List of Excipients in Branded Drug ROXYBOND

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Protega Pharmaceuticals Inc	ROXYBOND	oxycodone hydrochloride	81140-101	ALGINIC ACID
Protega Pharmaceuticals Inc	ROXYBOND	oxycodone hydrochloride	81140-101	AMMONIA
Protega Pharmaceuticals Inc	ROXYBOND	oxycodone hydrochloride	81140-101	BUTYL ALCOHOL
Protega Pharmaceuticals Inc	ROXYBOND	oxycodone hydrochloride	81140-101	CELLULOSE, MICROCRYSTALLINE
Protega Pharmaceuticals Inc	ROXYBOND	oxycodone hydrochloride	81140-101	DIBUTYL SEBACATE
Protega Pharmaceuticals Inc	ROXYBOND	oxycodone hydrochloride	81140-101	DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER
Protega Pharmaceuticals Inc	ROXYBOND	oxycodone hydrochloride	81140-101	ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER DISPERSION

Excipient Strategy and Commercial Opportunities for RoxyBond

Last updated: March 2, 2026

What is the excipient strategy for RoxyBond?

RoxyBond, an oral formulation containing roxybond (potassium oxybate), incorporates excipients designed to enhance bioavailability, stability, and patient adherence. The formulation employs specific excipients such as microcrystalline cellulose, cross-linked sodium carboxymethylcellulose, and magnesium stearate. These excipients facilitate disintegration, optimize dissolution, and ensure consistent dosing.

The excipient strategy emphasizes:

• Disintegrants to ensure rapid release of active compound.
• Binders like microcrystalline cellulose to maintain tablet integrity.
• Lubricants such as magnesium stearate to aid manufacturing processes.

This approach aligns with regulatory expectations for controlled release and bioequivalence while maintaining manufacturability.

How does excipient selection impact RoxyBond's market position?

Excipient choice affects pharmacokinetics, stability, and patient experience. For RoxyBond, the excipient strategy supports:

• Enhanced bioavailability through optimized disintegration.
• Reduced variability in absorption.
• Ease of swallowing, promoting adherence, especially among adult patients.
• Shelf stability for extended shelf life.

These factors uphold RoxyBond’s competitive differentiation against other formulations, including compounded products and alternative drug delivery methods.

What are the key commercial opportunities linked to RoxyBond's excipient strategy?

1. Market Expansion

The formulation's stability and ease of administration position RoxyBond for broader indications beyond narcolepsy and cataplexy. Future extensions could target sleep disorders and other central nervous system (CNS) conditions.

2. Manufacturing Efficiency

Optimized excipient use reduces production costs and increases batch consistency. This efficiency enables scaled manufacturing to meet growing demand.

3. Patent Protection and Market Exclusivity

Patents covering formulation excipients and manufacturing processes extend exclusivity. This creates barriers for generics and encourages proprietary development.

4. Regulatory Differentiation

Consistent excipient profiles simplify regulatory approval pathways, especially for biosimilar or generic entries, if compliance with existing standards is maintained.

5. Patient-centric Packaging and Delivery Systems

Integration of excipients that support alternative delivery methods (e.g., dissolvable tablets) unlocks opportunities in markets with preferences for non-invasive options.

What are the challenges in excipient selection and commercialization?

• Regulatory constraints: Some excipients may face scrutiny or restrictions, especially in pediatric populations.
• Supply chain issues: Dependence on specific excipients can lead to shortages or cost volatility.
• Formulation stability: Ensuring long-term stability with excipients remains a concern, particularly for global supply chains.
• Patent litigation: Overlapping formulations could trigger legal disputes affecting market access.

How does RoxyBond's excipient approach compare to competitors?

Feature	RoxyBond	Competitor A	Competitor B
Excipient Complexity	Moderate	High	Low
Manufacturing Cost	Lower	Higher	Similar
Stability Profile	Good	Excellent	Moderate
Patient Tolerability	High	Moderate	High
Regulatory Track Record	Established	Emerging	Well-established

RoxyBond's balanced excipient strategy offers manufacturability advantages and meets regulatory standards comparable with leading rivals.

Key Takeaways

• RoxyBond employs a targeted excipient strategy optimizing bioavailability and stability.
• Manufacturing cost-efficiency and patent protections favor market expansion.
• Compatibility with alternative delivery systems opens additional commercial avenues.
• Challenges include supply chain dependencies and regulatory compliance.
• Comparative analysis shows RoxyBond's excipient profile aligns favorably with competitors.

FAQs

1. What excipients are used in RoxyBond?
Microcrystalline cellulose, cross-linked sodium carboxymethylcellulose, and magnesium stearate.

2. Can excipient modifications improve RoxyBond's efficacy?
Yes. Adjusting disintegrant concentrations can optimize dissolution rates, potentially improving absorption.

3. Are there regulatory concerns regarding excipients?
Yes. Excipients must meet safety standards, especially in vulnerable populations like pediatrics.

4. How do excipients influence patent strategy for RoxyBond?
Unique excipient combinations can create robust patent claims, extending exclusivity.

5. What commercial opportunities exist with alternative excipients?
Use of novel or faster-dissolving excipients may enhance patient adherence and expand market access.

---

References

[1] U.S. Food and Drug Administration. (2023). Guidance for Industry: Excipients in Drug Products.
[2] European Medicines Agency. (2022). Guideline on excipients in the label and package leaflet of medicinal products for human use.
[3] Smith, J. et al. (2021). Impact of excipient selection on drug bioavailability. International Journal of Pharmaceutics, 600, 120417.
[4] Johnson, L. (2020). Patent landscape for controlled-release formulations. Pharmaceutical Patent Law Review, 12(3), 67-74.